These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Architecture of a SARS-CoV-2 mini replication and transcription complex. Yan L; Zhang Y; Ge J; Zheng L; Gao Y; Wang T; Jia Z; Wang H; Huang Y; Li M; Wang Q; Rao Z; Lou Z Nat Commun; 2020 Nov; 11(1):5874. PubMed ID: 33208736 [TBL] [Abstract][Full Text] [Related]
25. Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription Complex Reveals an Intermediate State in Cap Synthesis. Yan L; Ge J; Zheng L; Zhang Y; Gao Y; Wang T; Huang Y; Yang Y; Gao S; Li M; Liu Z; Wang H; Li Y; Chen Y; Guddat LW; Wang Q; Rao Z; Lou Z Cell; 2021 Jan; 184(1):184-193.e10. PubMed ID: 33232691 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13). Ugurel OM; Mutlu O; Sariyer E; Kocer S; Ugurel E; Inci TG; Ata O; Turgut-Balik D Int J Biol Macromol; 2020 Nov; 163():1687-1696. PubMed ID: 32980406 [TBL] [Abstract][Full Text] [Related]
27. Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection. Wei J; Alfajaro MM; DeWeirdt PC; Hanna RE; Lu-Culligan WJ; Cai WL; Strine MS; Zhang SM; Graziano VR; Schmitz CO; Chen JS; Mankowski MC; Filler RB; Ravindra NG; Gasque V; de Miguel FJ; Patil A; Chen H; Oguntuyo KY; Abriola L; Surovtseva YV; Orchard RC; Lee B; Lindenbach BD; Politi K; van Dijk D; Kadoch C; Simon MD; Yan Q; Doench JG; Wilen CB Cell; 2021 Jan; 184(1):76-91.e13. PubMed ID: 33147444 [TBL] [Abstract][Full Text] [Related]
28. Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells. Daniloski Z; Jordan TX; Wessels HH; Hoagland DA; Kasela S; Legut M; Maniatis S; Mimitou EP; Lu L; Geller E; Danziger O; Rosenberg BR; Phatnani H; Smibert P; Lappalainen T; tenOever BR; Sanjana NE Cell; 2021 Jan; 184(1):92-105.e16. PubMed ID: 33147445 [TBL] [Abstract][Full Text] [Related]
29. Mutations of SARS-CoV-2 nsp14 exhibit strong association with increased genome-wide mutation load. Eskier D; Suner A; Oktay Y; Karakülah G PeerJ; 2020; 8():e10181. PubMed ID: 33083157 [TBL] [Abstract][Full Text] [Related]
30. Discovery of COVID-19 Inhibitors Targeting the SARS-CoV-2 Nsp13 Helicase. White MA; Lin W; Cheng X J Phys Chem Lett; 2020 Nov; 11(21):9144-9151. PubMed ID: 33052685 [TBL] [Abstract][Full Text] [Related]
31. Structural insight into the recognition of Mahalapbutr P; Kongtaworn N; Rungrotmongkol T Comput Struct Biotechnol J; 2020; 18():2757-2765. PubMed ID: 33020707 [TBL] [Abstract][Full Text] [Related]
32. Minireview of progress in the structural study of SARS-CoV-2 proteins. Zhu G; Zhu C; Zhu Y; Sun F Curr Res Microb Sci; 2020 Sep; 1():53-61. PubMed ID: 33236001 [TBL] [Abstract][Full Text] [Related]
33. Reprofiling of approved drugs against SARS-CoV-2 main protease: an in-silico study. Kumar P; Bhardwaj T; Kumar A; Gehi BR; Kapuganti SK; Garg N; Nath G; Giri R J Biomol Struct Dyn; 2022 Apr; 40(7):3170-3184. PubMed ID: 33179586 [TBL] [Abstract][Full Text] [Related]
34. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205 [TBL] [Abstract][Full Text] [Related]
35. Crystal Structure of Non-Structural Protein 10 from Severe Acute Respiratory Syndrome Coronavirus-2. Rogstam A; Nyblom M; Christensen S; Sele C; Talibov VO; Lindvall T; Rasmussen AA; André I; Fisher Z; Knecht W; Kozielski F Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036230 [TBL] [Abstract][Full Text] [Related]
36. The Enzymatic Activity of the nsp14 Exoribonuclease Is Critical for Replication of MERS-CoV and SARS-CoV-2. Ogando NS; Zevenhoven-Dobbe JC; van der Meer Y; Bredenbeek PJ; Posthuma CC; Snijder EJ J Virol; 2020 Nov; 94(23):. PubMed ID: 32938769 [TBL] [Abstract][Full Text] [Related]
37. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Koenig PA; Das H; Liu H; Kümmerer BM; Gohr FN; Jenster LM; Schiffelers LDJ; Tesfamariam YM; Uchima M; Wuerth JD; Gatterdam K; Ruetalo N; Christensen MH; Fandrey CI; Normann S; Tödtmann JMP; Pritzl S; Hanke L; Boos J; Yuan M; Zhu X; Schmid-Burgk JL; Kato H; Schindler M; Wilson IA; Geyer M; Ludwig KU; Hällberg BM; Wu NC; Schmidt FI Science; 2021 Feb; 371(6530):. PubMed ID: 33436526 [TBL] [Abstract][Full Text] [Related]
38. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Tortorici MA; Beltramello M; Lempp FA; Pinto D; Dang HV; Rosen LE; McCallum M; Bowen J; Minola A; Jaconi S; Zatta F; De Marco A; Guarino B; Bianchi S; Lauron EJ; Tucker H; Zhou J; Peter A; Havenar-Daughton C; Wojcechowskyj JA; Case JB; Chen RE; Kaiser H; Montiel-Ruiz M; Meury M; Czudnochowski N; Spreafico R; Dillen J; Ng C; Sprugasci N; Culap K; Benigni F; Abdelnabi R; Foo SC; Schmid MA; Cameroni E; Riva A; Gabrieli A; Galli M; Pizzuto MS; Neyts J; Diamond MS; Virgin HW; Snell G; Corti D; Fink K; Veesler D Science; 2020 Nov; 370(6519):950-957. PubMed ID: 32972994 [TBL] [Abstract][Full Text] [Related]
39. Unraveling the stability landscape of mutations in the SARS-CoV-2 receptor-binding domain. Smaoui MR; Yahyaoui H Sci Rep; 2021 Apr; 11(1):9166. PubMed ID: 33911163 [TBL] [Abstract][Full Text] [Related]
40. Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2. Kumar D T; Shaikh N; Kumar S U; Doss C GP; Zayed H Front Mol Biosci; 2021; 8():645216. PubMed ID: 33898520 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]